- Home
- WGRX vs ENTA Comparison
WGRX vs ENTA Comparison
Compare WGRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGRX
- ENTA
- Stock Information
- Founded
- WGRX 2022
- ENTA 1995
- Country
- WGRX United States
- ENTA United States
- Employees
- WGRX N/A
- ENTA N/A
- Industry
- WGRX Other Pharmaceuticals
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- WGRX Health Care
- ENTA Health Care
- Exchange
- WGRX Nasdaq
- ENTA Nasdaq
- Market Cap
- WGRX 140.2M
- ENTA 154.0M
- IPO Year
- WGRX 2025
- ENTA 2013
- Fundamental
- Price
- WGRX $4.32
- ENTA $5.59
- Analyst Decision
- WGRX
- ENTA Buy
- Analyst Count
- WGRX 0
- ENTA 4
- Target Price
- WGRX N/A
- ENTA $17.25
- AVG Volume (30 Days)
- WGRX 184.2K
- ENTA 228.9K
- Earning Date
- WGRX 01-01-0001
- ENTA 05-05-2025
- Dividend Yield
- WGRX N/A
- ENTA N/A
- EPS Growth
- WGRX N/A
- ENTA N/A
- EPS
- WGRX N/A
- ENTA N/A
- Revenue
- WGRX $18,128,831.00
- ENTA $66,590,999.00
- Revenue This Year
- WGRX N/A
- ENTA N/A
- Revenue Next Year
- WGRX N/A
- ENTA N/A
- P/E Ratio
- WGRX N/A
- ENTA N/A
- Revenue Growth
- WGRX N/A
- ENTA N/A
- 52 Week Low
- WGRX $2.32
- ENTA $4.71
- 52 Week High
- WGRX $5.69
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- WGRX N/A
- ENTA 31.66
- Support Level
- WGRX N/A
- ENTA $5.65
- Resistance Level
- WGRX N/A
- ENTA $5.96
- Average True Range (ATR)
- WGRX 0.00
- ENTA 0.36
- MACD
- WGRX 0.00
- ENTA -0.15
- Stochastic Oscillator
- WGRX 0.00
- ENTA 4.77
About WGRX Wellgistics Health Inc. Common Stock
Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a seamless prescription ecosystem through an integrated technology platform, wholesale distribution, and fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.